Business Wire

Amazon study reveals most European employees favour on-the-job skills training or apprenticeships over university degrees for a successful career start

Share

More than half of European workers (54%) believe that on-the-job-skills training or apprenticeships are more valuable for preparing people for work today than traditional university degrees, a new European career insights and workplace trends study commissioned by Amazon has found. In fact, the study found that just under three quarters (73%) of workers feel there needs to be a wider range of apprenticeship or internship opportunities available to young people.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240613014196/en/

The Amazon Future of Work & Career Development European study, conducted by Ipsos, also found that a majority of European employees* (89%) think it’s important to learn a new skill to improve or change their career path, even more so than receiving a promotion (73%). Alongside factors such as pay/salary (94%) and office/worksite location or flexible/hybrid or remote working (93%), 91% of adults say on the job training or career development training is essential or important when looking for a new job or role, and that training programmes offered by a potential employer are more important than company culture (78%). One potential reason is that many workers in the study said it would make them feel motivated (39%), encouraged (32%), valued (31%) or supported (30%) to work for a company that provides access to career development training. Additionally, almost one in five workers in Europe (19%) admit they couldn’t afford to pay for training.

Amazon has long adapted to the ever-changing career and education landscape, investing more than €100 million in training programmes in Europe since it launched its Career Choice programme in the region in 2014. The programme provides 95% of pre-paid tuition, up to €8,000 over four years, for nationally recognised courses from more than 85 schools throughout Europe. It offers various training opportunities in a range of popular, in-demand job fields, from tech and sustainability to business administration and logistics, for Amazon’s hourly and salaried workers across the region.

To mark the ten-year anniversary of Career Choice in Europe, Amazon plans to invest €40 million in 2024 and to add more than 25 new programmes across five countries in Europe this year to support current and future job needs for the thousands of employees who participate in Career Choice. Currently, Amazon employees in Europe have access to over a hundred different programmes to help them maximise their potential within the company or outside of Amazon. Some of the new courses added in 2024 include Cloud Support, Cyber Security, Information Security, Web and Graphic Design, Mechatronics, Procurement Logistics, and Big Data, Virtualisation, and Machine Learning.

Since its launch ten years ago, more than 40,000 Amazon employees across Europe** have participated in the programme. While some employees leave Amazon to pursue other career opportunities with their newly acquired skills and certifications from Career Choice, thousands have stayed and transitioned into new roles. The popularity of the programme continues to increase, with about one in ten of all eligible employees in Europe participating in Career Choice in 2023. Popular areas of study vary from technology and sustainability, to mechanical and industrial systems, transportation and logistics, and administration and business studies.

“I attribute a lot of my growth at Amazon to Career Choice,” said Mo Abdullahi, Senior Operations Manager and Career Choice participant number four in the UK from 2014. “It gave me an opportunity to learn more about the role that I wanted and helped me with obtaining the qualifications that I needed. I'm still super surprised of my journey and growth through Amazon. If I look back ten years ago and starting as a temporary worker, I certainly wouldn't have assumed that I would be at the level I am right now and with the responsibility I have now. It’s been an incredible journey.”

When it comes to jobs in the future, the study shows that training will need to play a key role in alleviating worker concerns, as 32% of European workers are worried they won’t have the training and skills to be relevant in their job in the coming years. In fact, two-thirds of European workers (67%) believe that people in the workforce today will need to continue to retrain and update their skills to continue working in the future. However, only 15% of employees say they have access to training to help them change their career path, and over one in five (22%) employees say they don’t have any access to training with their current employer.

“The latest research and the growth of our Career Choice programme over the past ten years clearly demonstrates the strong desire for workers across the Europe to develop their careers through relevant and accessible skills training programmes,” said Robert Marhan, Global Operations Vice President of People Experience & Technology (PXT). “Amazon is proud to celebrate the tenth anniversary of the Career Choice skills training programme in Europe and to expand the course options available, so that thousands of employees across Europe can advance their skills and take on new career opportunities both at Amazon and beyond.”

The Career Choice programme is currently available to Amazon employees in Australia, Canada, Costa Rica, Czech Republic, France, Germany, Ireland, Italy, Poland, Slovakia, South Africa, Spain, the U.S., and the UK. It has a rigorous selection process for third-party partner educators, choosing partners that are focused on helping employees through their education programmes, assisting them with job placements, and overall offering education that leads to career success.

To learn more about the Career Choice programme, visit Amazon Career Choice https://www.aboutamazon.eu/news/tag/working-at-amazon/career-choice

Sources:

*The research was carried out by Ipsos UK on behalf of Amazon. Ipsos UK interviewed a representative quota sample of 16,482 adults using its online omnibus, and within that a sample of 9,686 employees. Fieldwork was carried out in 8 markets across Europe, including Spain, Germany, UK, France, Italy, Slovakia, Czech Republic, Poland. The sample achieved is representative of the population aged 16-75 in all markets except Czech Republic and Slovakia, where the participants were aged 16-65. Interlocking quotas were set on Age within Gender, and on Region and Working status. The data has been weighted to the known offline population proportions for interlocking cells of gender within age and working status, as well as region and education to reflect the adult population of each market. A country average weight was also applied. Fieldwork was carried out between the 26th April and 27th May 2024. This research was conducted as part of a global study across Australia, Canada, Czech Republic, France, Germany, Italy, Poland, South Africa, Slovakia, Spain, and the UK.

**Amazon Career Choice participation data collected in Europe between 2014-24.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240613014196/en/

Contacts

Louise Thach thachl@amazon.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

SBC Medical Accelerates Multi-Brand Strategy with Hybrid Dermatology Model “Hada no Aozora Clinic” Establishment17.9.2025 15:00:00 EEST | Press release

SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical”), a global provider of comprehensive consulting and management services to the medical corporations and their clinics, today announced the launch of a new brand, “Hada no Aozora Clinic”, scheduled to open in Tokyo on October 1, 2025. This clinic will adopt a hybrid dermatology model that integrates insurance-covered general dermatology and private-pay aesthetic treatments, advancing SBC’s multi-brand strategy in the rapidly expanding aesthetic medicine market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250917897380/en/ SBC Medical Accelerates Multi-Brand Strategy with Hybrid Dermatology Model “Hada no Aozora Clinic” Establishment As life expectancy continues to rise and demographic aging accelerates, more people are seeking treatments that help them maintain both well-being and a youthful appearance over a longer lifespan. Within this environment, aesth

Merck to Present New Data Highlighting Durable Effects of MAVENCLAD ® in Relapsing Multiple Sclerosis (RMS) at ECTRIMS 202517.9.2025 15:00:00 EEST | Press release

Not intended for UK-, US- or Canada-based media Merck, a leading science and technology company, today announced the presentation of over 30 abstracts from its multiple sclerosis (MS) portfolio. New four-year data from two large Phase 4 studies highlight the long-term efficacy, favorable disability outcomes and durable impact of MAVENCLAD® (cladribine tablets) in people living with relapsing multiple sclerosis (RMS). These findings are to be presented at the 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), being held September 24-26 in Barcelona. “As the only high-efficacy short-course oral treatment, MAVENCLAD has demonstrated sustained benefits across a variety of outcomes—extending beyond relapses and MRI—without requiring continuous immunosuppression,” said Alex Kulla, Senior Vice President & Global Head of the Neurology & Immunology Medical Unit for the Healthcare business of Merck. “With over two decades of clinical experience an

Rubedo Life Sciences Announces U.S. FDA Clearance of IND for Selective GPX4 Modulating Lead Drug Candidate RLS-1496 for Actinic Keratosis, Expands Clinical Advisory Board17.9.2025 15:00:00 EEST | Press release

Rubedo Life Sciences, Inc. (Rubedo), an AI-driven, clinical-stage biotech focused on discovering and rapidly developing selective cellular rejuvenation medicines targeting aging cells, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for a Phase 1b/2a study with lead drug candidate RLS-1496 in patients with actinic keratosis. RLS-1496 is a first-in-class disease-modifying selective glutathione peroxidase 4 (GPX4) modulator targeting pathological senescent cells that drive inflammaging and chronic degenerative diseases and conditions associated with the biological aging process. The study is expected to begin in Q4 2025. The first EMA-cleared RLS-1496 clinical trial began in May 2025 for plaque psoriasis, atopic dermatitis, and skin aging (photoaged skin); study results are expected in Q4 2025. Actinic keratosis is a rough, scaly patch caused by sun exposure that appears on sun-exposed areas of the skin, such as

New Study Finds That Using Masimo Technologies to Continuously Monitor General Floor Patients Reduces Costs17.9.2025 15:00:00 EEST | Press release

Masimo (NASDAQ: MASI) today announced the findings of a study published in the Journal of Patient Safety in which Dr. George Blike and colleagues at Dartmouth-Hitchcock Medical Center in New Hampshire demonstrated that use of Masimo technologies to continuously monitor general floor patients can yield significant cost savings.1 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250917266545/en/ Continuous Patient Monitoring with Masimo SET® Pulse Oximetry and Patient SafetyNet™ In prior studies, the clinical outcome benefits of continuously monitoring patients using Masimo SET® and Patient SafetyNet™ have been shown to include lower mortality, improved resuscitative outcomes, and fewer rapid response team activations and transfers to higher-acuity care units, achieved through earlier detection and intervention to prevent patient deterioration.2-5 Now, in this new retrospective analysis – involving 3-1/2 years of data and almost

Kinectrics Significantly Increases Isotope Production Capacity to Meet Growing Global Demand17.9.2025 14:30:00 EEST | Press release

Kinectrics, a division of BWX Technologies Inc. (NYSE: BWXT), announced today the completion of a major expansion to its isotope production capabilities, reinforcing its role as a global supplier of highly enriched stable isotopes and establishing the only North American source for Yb-176, reducing the reliance on foreign material for life-saving cancer treatments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250917450864/en/ Travis Besanger, Kinectrics VP of Medical Isotopes, speaking within the new Isotope Separation Production Facility at Kinectrics Headquarters in Toronto, Canada. Kinectrics commissioned four new 2nd generation Electromagnetic Isotope Separator (EMIS) units, which will boost its annual production capacity to over 500 grams of Ytterbium-176 (Yb-176), the precursor for Lutetium-177 (Lu-177), by the end of the year. This scaled output will support over 150,000 patient treatments annually. Lu-177 is a medi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye